Sanofi
-
Sanofi hits reset on drug from $2.5B deal after ‘lower than projected’ efficacy in trials
Sanofi did not see the efficacy it wanted in mid-stage tests of a cytokine therapy from its $2.5 billion acquisition of Synthorx. While the pharmaceutical giant isn’t giving up on the drug, it said it will restart the molecule in a new Phase 1/2 program, a setback that will lead to a €1.6 billion financial writedown.
-
Artificial Intelligence, BioPharma
Sanofi exec jumps to Owkin to ramp up the AI biotech’s pharma partnership plans
Alban de La Sablière, global head of partnering at Sanofi for the past six years, has joined artificial intelligence biotech Owkin as its first chief business officer. In addition to finding more business partnerships, de La Sablière will also oversee expansion of Owkin’s internal drug and diagnostics pipeline.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Sanofi’s RNA therapies strategy adds new piece with alliance in muscular dystrophy
Sanofi is collaborating with startup miRecule to develop an RNA therapy for facioscapulohumeral muscular dystrophy. The pharmaceutical giant gets global rights to miRecule’s therapy for this type of muscular dystrophy, which has no FDA-approved treatments.
-
Sanofi turns to startup Scribe to CRISPR edit new NK cell therapies for cancer
Sanofi is collaborating with Scribe Therapeutics to use the startup’s CRISPR technology to create cell therapies based on natural killers, a type of immune cell that has cancer-killing capabilities. The pharma giant is paying Scribe $25 million up front to kick off the deal.
-
Sanofi drops out of competitive breast cancer drug race after another trial failure
Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule. The move means Sanofi is out of the competitive chase to develop a so-called “oral SERD” therapy for patients with a certain type of breast cancer.
-
As M&A costs rise, new Accenture report offers alternative strategies
Rising deal premiums and shrinking profit margins are threatening the sustainability of the traditional approach to mergers and acqusitions, according to a report by Accenture. The firm expects growth-minded companies will turn to other pathways.
-
Liver injury leads FDA to pause Sanofi’s tests of MS drug acquired in $3.7B deal
The FDA placed a partial clinical hold on late-stage tests of Sanofi multiple sclerosis drug tolebrutinib after some patients developed drug-induced liver injury. While U.S. tests are paused, Sanofi said clinical testing in other countries is continuing with additional safety monitoring.
-
Two for two: Sanofi snares twin European nods for enzyme replacement therapies
Sanofi won European Commission approval for two therapies that treat rare enzyme deficiencies. Xenpoyzme is the first treatment for acid sphingomyelinase deficiency (ASMD) while Nexviadyme is a successor to a blockbuster Sanofi drug for Pompe disease.
-
BrightInsight launches new digital disease management solution for biopharma and medtech
BrightInsight developed the Disease Management Solution to help biopharma and medtech companies bring their Software as a Medical Device (SaMD) to market faster, according to BrightInsight CEO and Co-founder Dr. Kal Patel.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
Regeneron is paying $900M for full rights to cancer drug partnered with Sanofi
Regeneron Pharmaceuticals has big plans for cancer immunotherapy Libtayo and it believes it can better execute on them if it has full control of the drug, currently partnered with Sanofi. Regeneron struck a deal to pay Sanofi $900 million, plus another $200 million in milestones, to secure full global rights to the asset.
-
Roche breast cancer drug fails in Phase 2 following similar stumble by rival Sanofi
Experimental Roche drug giredestrant failed to meet the main goal of a Phase 2 study in advanced breast cancer. The disappointing results allow competitors to gain ground in the field of companies developing oral selective estrogen receptor degraders (SERDs), drugs that block a receptor key to driving breast cancer growth.
-
Sanofi and Seagen team up to grow a new crop of ADC cancer drugs
Antibody drug conjugates have made scientific and regulatory progress in recent years. Sanofi is partnering with ADC specialist Seagen in a multi-drug alliance that keeps the pharmaceutical giant in the mix of this growing field of cancer therapies.
-
Sanofi’s hemophilia A data set stage for regulatory filings, matchup with Roche
An experimental hemophilia A therapy from Sanofi and partner Sobi has met the goals of a pivotal study, and the pharmaceutical giant is now planning global regulatory submissions for later this year. The drug could compete against a blockbuster hemophilia A treatment marketed by Roche.
-
Artificial Intelligence, BioPharma, Health Tech
Sanofi and DarioHealth team up on digital health tools for chronic conditions
Sanofi and digital therapeutics company DarioHealth will work together to promote the tech firm’s offerings for the management of chronic diseases. Under the $30 million, multi-year agreement, the partners will also develop new technology tools.
-
Sanofi, GSK Covid-19 vax is now ready for regulators; its future may be as a booster
Sanofi and GlaxoSmithKline weathered clinical trial delays for their Covid-19 vaccine, but the partners now have data to support filings seeking regulatory authorizations. Key features of the vaccine may be able to persuade the vaccine hesitant; it may also be well-suited for use as a booster.